Curated News
By: NewsRamp Editorial Staff
July 13, 2026
Tonix Scores Major Medicare Deal for TONMYA, Covering 145M Lives
TLDR
- Tonix Pharmaceuticals expands TONMYA coverage to 145 million lives, gaining competitive edge in fibromyalgia market.
- Tonix adds 50 sales reps by mid-2026, boosting force to 150, to drive TONMYA adoption through managed care agreements.
- TONMYA offers first non-opioid fibromyalgia treatment in 15 years, improving quality of life for millions.
- TONMYA's novel sublingual formulation provides rapid absorption, differentiating it from traditional oral medications.
Impact - Why it Matters
This news matters because it expands access to a non-opioid treatment for fibromyalgia, a chronic pain condition affecting millions of Americans. With Medicare and commercial coverage reaching nearly half the U.S. market, patients now have a new, potentially safer option for managing their symptoms. Tonix's move to increase its sales force signals confidence in TONMYA's adoption, offering hope to those who have had limited treatment choices for over a decade. The broader coverage could reduce reliance on opioids and improve quality of life for many fibromyalgia sufferers.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a significant managed Medicare agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective January 1, 2027. This new coverage, combined with previously announced commercial agreements and broad Medicaid availability, means TONMYA will have pharmacy coverage reaching roughly 145 million covered lives, or 46% of the U.S. covered market. The company continues discussions with additional commercial and Medicare payers, aiming to further expand access to this first-in-class, non-opioid treatment for fibromyalgia.
With the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company is also expanding marketing and medical affairs initiatives to raise awareness of TONMYA as a novel therapy for fibromyalgia, a condition that has not seen a new FDA-approved treatment in over 15 years. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, Tonix’s CNS commercial infrastructure supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is also advancing a pipeline including TNX-2900 for Prader-Willi syndrome and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection.
This milestone underscores Tonix's commitment to delivering innovative therapies to patients. The company's product development candidates remain investigational; their efficacy and safety have not been established for any indication. For the latest updates, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/tVAj3.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Scores Major Medicare Deal for TONMYA, Covering 145M Lives
